InflaRx N.V. (IFRX) Earnings Call Transcripts

InflaRx N.V.'s Latest Earnings Call - May 8, 2026

In the Q1 2026 earnings call for InflaRx N.V. (IFRX:US), management emphasized the strategic focus on the development of izicopan, an oral C5a receptor inhibitor targeting ANCA-associated vasculitis and other renal diseases. The company highlighted the potential for izicopan to capture a significant share of the $1.3 billion market currently dominated by avacopan, particularly due to its differentiated safety and efficacy profile. While specific revenue figures were not disclosed, the management expressed optimism about the drug's market potential and indicated plans for expedited regulatory discussions with the FDA, which could enhance the timeline for clinical trials and market entry.

Reported metrics

Guidance from management

Management is optimistic about izicopan's potential and plans to initiate a Phase II trial with a focus on rapid enrollment and efficacy signals. They aim to engage with the FDA for expedited development pathways.

What management said

Good morning, everyone. Thank you for standing by, and thank you for joining our conference call this morning to discuss our recently announced effort to pursue izicopan for AAV and other renal diseases. [Operator Instructions] Please note that today's call is also being recorded. [Operator Instructions] I would now like to turn the call over to Niels Riedemann, CEO and Founder of InflaRx. Niels, please go ahead.

Great. And then I think just reiterate a bit on the other renal indications we talked about, we think we can start showing some data next year on the IgAN, aHUS and CG3 [ in ] one or more of those next year. Okay. So in the -- moving on quickly, I want a couple of questions we have that were submitted to us in writing. The first one is from Sam Slutsky at LifeSci Capital asking that based on your PK/PD data, what go...

What analysts pressed on

Analysts expressed concerns regarding the potential market impact if avacopan were to be withdrawn and questioned the efficacy signals of izicopan compared to avacopan. There were also inquiries about the company's strategy for patient enrollment and trial design in light of the competitive landscape.

Main topics on the call

• Focus on Izicopan Development — Management reiterated their commitment to izicopan, stating it has 'best-in-class potential' due to its 'very fast onset of action' and 'clean safety profile'. They believe izicopan can address multiple renal diseases, e...
• Regulatory Strategy — InflaRx plans to engage with the FDA for a potential expedited path to market, with CEO Niels Riedemann stating, 'we want to discuss this relatively soon' to explore a seamless Phase II/III trial approach.
• Market Potential and Physician Feedback — Management highlighted strong physician interest in izicopan, with a survey indicating that 'currently, they treat roughly about 15% and mean it could go up to 55%'. This suggests significant room for market penetration.
• Differentiation from Avacopan — Riedemann addressed concerns regarding avacopan's safety issues, asserting that 'there is no reason to believe there's a class effect' and emphasizing izicopan's differentiated metabolic stability and safety profile.

Read the full InflaRx N.V. transcript (May 8, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 14 InflaRx N.V. earnings call transcripts on record, spanning January 16, 2020 to May 8, 2026. Based on this history, InflaRx N.V. reports semi-annually. The most recent call on file is dated May 8, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

IFRX

Exchange

NasdaqGS

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

14

First call

January 16, 2020

Most recent

May 8, 2026

Reporting cadence

semi-annually